Michele Schiappoli

University of Verona — Italy

Medicine · Health Sciences

19h-index1.1kcitations76works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Allergic Rhinitis and Sensitization(38), Asthma and respiratory diseases(30), Food Allergy and Anaphylaxis Research(21), Contact Dermatitis and Allergies(12), Sinusitis and nasal conditions(9)

Publications76 total

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An <scp>EAACI</scp> Task Force Report
Allergy·2026
The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways—An <scp> <b>EAACI</b> </scp> Position Paper
Allergy·2026
When hypereosinophilia occurs during dupilumab therapy: evidence-based strategies for clinical management in respiratory indications
Expert Review of Respiratory Medicine·2025· 1 cited
Allergological Work‐Up in Cephalosporin Allergy Diagnosis and Delabelling: The Experience From Two European Allergy Centres
Allergy·2025
Otitis Media With Effusion (<scp>OME</scp>) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An <scp>EAACI</scp> Position Paper
Allergy·2025· 10 citedOpen Access
Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An EAACI Position Paper
Universität Zürich, ZORA·2025Open Access
Mepolizumab in severe uncontrolled CRSwNP: a real-life multicentre study in Northeast Italy
Rhinology Journal·2025· 2 cited
Profiling Blood Hypereosinophilia in Patients on Dupilumab Treatment for Respiratory Conditions: A Real-Life Snapshot
The Journal of Allergy and Clinical Immunology In Practice·2025· 3 citedOpen Access
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach
World Allergy Organization Journal·2024· 9 citedOpen Access
Obituary: Professor Peter Valentin Tomazic, Graz, Austria
Allergy·2024Open Access
Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker?
Allergy·2024· 12 citedOpen Access
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter
Journal of Clinical Medicine·2024· 8 citedOpen Access
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective
Biomedicines·2024· 12 citedOpen Access
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence
Expert Opinion on Biological Therapy·2024· 13 citedOpen Access
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps
Current Allergy and Asthma Reports·2023· 21 citedOpen Access
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis
Lara D. Veeken·2023· 5 cited
Immunoglobulin Free Light Chains in Severe Asthma Patient: could they be a new biomarker?
2023Open Access
Resensitization in suspected penicillin allergy
Allergy·2022· 26 citedOpen Access
Different aspects of severe asthma in real life: Role of <i>Staphylococcus aureus</i> enterotoxins and correlation to comorbidities and disease severity
Allergy·2022· 25 cited
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management
Expert Review of Respiratory Medicine·2022· 92 cited
page 1 of 4Next →

Frequent Co-authors

Gianenrico Senna(43), Giovanni Passalacqua(20), Marco Caminati(17), Annarita Dama(16), Patrizia Bonadonna(12), Mariangiola Crivellaro(11), Giorgio Walter Canonica(9), Claudio Micheletto(7), Riccardo C. Bonadonna(7), Diego Bagnasco(6), Bianca Olivieri(5), Erminia Ridolo(5), Patrick Pinter(4), Beatrice Caruso(4), Elisa Olivieri(4), Luisa Brussino(4), Stefano Del Giacco(4), Enrico Heffler(4), Andrea Vianello(4), Giorgio Piacentini(4)